193 related articles for article (PubMed ID: 23347986)
1. Optional copayments on anti-cancer drugs.
van de Vooren K; Curto A; Garattini L
BMJ; 2013 Jan; 346():f349. PubMed ID: 23347986
[No Abstract] [Full Text] [Related]
2. Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.
Garrison LP
Oncologist; 2010; 15 Suppl 1():49-57. PubMed ID: 20237218
[No Abstract] [Full Text] [Related]
3. [Innovative therapy, early and cost-benefit assessment].
Dierks C
Onkologie; 2012; 35 Suppl 2():7. PubMed ID: 22517064
[No Abstract] [Full Text] [Related]
4. [Pharmaceuticals can be cost-effective in the long run].
Jönsson B; Wilking N
Lakartidningen; 2010 Apr 21-27; 107(16):1081-5. PubMed ID: 20476706
[No Abstract] [Full Text] [Related]
5. Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies.
da Veiga CRP; da Veiga CP; Drummond-Lage AP
Crit Rev Oncol Hematol; 2018 Sep; 129():133-145. PubMed ID: 30097232
[TBL] [Abstract][Full Text] [Related]
6. Impact of Medicaid copayments on patients with cancer: lessons for Medicaid expansion under health reform.
Subramanian S
Med Care; 2011 Sep; 49(9):842-7. PubMed ID: 21577164
[TBL] [Abstract][Full Text] [Related]
7. Do oncologists believe new cancer drugs offer good value?
Nadler E; Eckert B; Neumann PJ
Oncologist; 2006 Feb; 11(2):90-5. PubMed ID: 16476830
[TBL] [Abstract][Full Text] [Related]
8. New cancer drugs at the cost of bankruptcy: will the oncologist tell the patients the benefit in terms of days/weeks added to life?
Garg PK; Jain BK
Oncologist; 2014 Dec; 19(12):1291. PubMed ID: 25480341
[TBL] [Abstract][Full Text] [Related]
9. GlaxoSmithKline cancer drug threatens Herceptin market.
Waltz E
Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
[No Abstract] [Full Text] [Related]
10. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
Hillner BE; Smith TJ
J Clin Oncol; 2007 Feb; 25(6):611-3. PubMed ID: 17308264
[No Abstract] [Full Text] [Related]
11. Adjuvant trastuzumab for breast cancer: an increasingly common ethical and economic conundrum.
Grove ML
BMJ; 2005 Nov; 331(7526):1202. PubMed ID: 16293847
[No Abstract] [Full Text] [Related]
12. [Economic effects of "molecular" medicine].
Riemann JF
Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1740. PubMed ID: 17713881
[No Abstract] [Full Text] [Related]
13. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
Low E;
J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
[No Abstract] [Full Text] [Related]
14. Health economics in the Journal of Clinical Oncology and an evaluation of the indirect costs and benefits associated with adjuvant trastuzumab.
de Lima Lopes G; Gluck S
J Clin Oncol; 2007 Aug; 25(22):3382-3; author reply 3383. PubMed ID: 17664490
[No Abstract] [Full Text] [Related]
15. Oral/infusion cancer drug parity begins to raise health plan costs.
Carroll J
Manag Care; 2012 Jan; 21(1):7-8. PubMed ID: 22334937
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
17. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
Yang H; Yu AP; Wu EQ; Yim YM; Yu E
J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
[TBL] [Abstract][Full Text] [Related]
18. Can treatment costs be tamed?
Malakoff D
Science; 2011 Mar; 331(6024):1545-7. PubMed ID: 21436438
[No Abstract] [Full Text] [Related]
19. [High cost of trastuzumab for the treatment of mammary carcinoma in The Netherlands].
Offerhaus L
Ned Tijdschr Geneeskd; 2006 Jun; 150(25):1426-7; author reply 1427. PubMed ID: 16841595
[No Abstract] [Full Text] [Related]
20. How much will Herceptin really cost? The money is already there.
Minhas R
BMJ; 2006 Dec; 333(7580):1219; discussion 1219-20. PubMed ID: 17158392
[No Abstract] [Full Text] [Related]
[Next] [New Search]
